ASO keywords
Most repeated terms in the listing. Highlighted ones also appear in the title.
nursing5oncology nursing3nursing drug3drug handbook3turned off3drug3updated3drugs3jblearning3nurses2cancer2oncology2handbook2annually2information2chapters2understanding2indications2injection2year2turned2off2renewal2
What's new in 2.0.2.104
Updated data
Framework improvements
Released May 31, 2018. Current version shipped Apr 17, 2020.
Store description
Written especially for nurses caring for patients with cancer, the Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include:
apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)
Subscriptions are $9.99 for one year. Your subscription will auto-renew annually at the end of each year-long term, unless cancelled. Payment will be charged to your iTunes Account at confirmation of purchase. The subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Your account will be charged $9.99 for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed and auto-renewal may be turned off by going to your Account Settings after purchase. No cancellation of the current subscription is allowed during active subscription period. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication. Please see the links to our privacy policy and terms of service below.
Privacy Policy - http://www.jblearning.com/privacy/
Terms of Use - http://www.jblearning.com/use/
Print Book - http://www.jblearning.com/catalog/9781284054613/
See this store page in another country
Prices, ranks and reviews are per country. Revenue above is already worldwide.
